Get the Stockscreener App
0.826
1.08%
-0.009
After Hours:
.82
-0.006
-0.73%
Invivyd Inc stock is traded at $0.826, with a volume of 1.96M.
It is down -1.08% in the last 24 hours and up +44.10% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$0.835
Open:
$0.82
24h Volume:
1.96M
Relative Volume:
0.42
Market Cap:
$243.47M
Revenue:
$55.87M
Net Income/Loss:
$-77.60M
P/E Ratio:
-2.3157
EPS:
-0.3567
Net Cash Flow:
$-79.46M
1W Performance:
-14.36%
1M Performance:
+44.10%
6M Performance:
-51.70%
1Y Performance:
-17.19%
1-Day Range:
$0.7901
$0.8269
1-Week Range:
$0.753
$1.01
52-Week Range:
$0.5277
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.826 | 280.26M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Invivyd stock holds steady as investors watch recent trial progress - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Invivyd stock falls as investors await VYD2311 data - AD HOC NEWS
Director at Invivyd (IVVD) granted 100K stock options - Stock Titan
No Invivyd (NASDAQ: IVVD) shares listed in company director's ownership filing - Stock Titan
Invivyd appoints Marc Elia CEO amid board reshuffle - The Globe and Mail
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
New multi-million-share option grant for Invivyd (IVVD) CEO - Stock Titan
Invivyd, Inc. Announces Board Appointments - marketscreener.com
New Haven COVID drugmaker names new CEO ahead of key trial results - Hartford Business Journal
Invivyd Names Chairman Marc Elia as CEO - marketscreener.com
Invivyd Names Marc Elia CEO, Adds New Independent Director as VYD2311 Phase 3 Studies Near Completion - Quiver Quantitative
Invivyd (IVVD) gives its new CEO rich equity and a potential 0.5%–1.5% payout on any sale worth at least $5B, as Phase 3 COVID antibody data near. - Stock Titan
Cantor Fitzgerald reiterates Invivyd stock rating on COVID trends - Investing.com
Invivyd (IVVD) Results Check: Profit Per Share Falls Below Its Benchmark on the Day; Price Move: The Stock Ends Up 2.65%Earnings Sentiment Score - vinanet.vn
Invivyd Stock (IVVD) Opinions on Upcoming Phase 3 Results - Moomoo
Invivyd (IVVD) Q1 2026 Results: The EPS Result Is Below Expectation; Closing Reaction: Shares Finish 10.53% Higher for the Current SessionEPS Revision Trend - vinanet.vn
FY2026 EPS Estimates for Invivyd Increased by HC Wainwright - MarketBeat
Invivyd CSO Robert Allen III sells $29,295 in stock By Investing.com - Investing.com South Africa
Invivyd chief legal officer Jill Andersen sells $52,780 in shares By Investing.com - Investing.com Australia
Invivyd CCO Timothy Lee sells $31,670 in shares By Investing.com - Investing.com Nigeria
Invivyd CFO William Duke sells $31,670 in company stock By Investing.com - Investing.com South Africa
Invivyd CFO William Duke sells $31,670 in company stock - Investing.com
Invivyd CHRO Julie Green sells $31,670 in company stock - Investing.com India
Invivyd CSO Robert Allen III sells $29,295 in stock - Investing.com
Invivyd chief legal officer Jill Andersen sells $52,780 in shares - Investing.com
Invivyd CCO Timothy Lee sells $31,670 in shares - Investing.com
Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 18,425 Shares of Stock - MarketBeat
Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $25,793.04 in Stock - MarketBeat
Invivyd (NASDAQ:IVVD) Insider Sells $26,824.32 in Stock - MarketBeat
Invivyd (IVVD) Closing Review: Moves 17.23% Up to $0.87; Current Setup: $0.83 and $0.91 Define the Nearby Reference Levels in Latest TradingLow Volatility Picks - vinanet.vn
Invivyd (IVVD) officer sells 37,256 and 30,706 shares under 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Invivyd stock rating on trial progress By Investing.com - Investing.com Canada
Invivyd (IVVD) Rises 2.72% to $0.74 as Buyers Defend Key Support at $0.70Rectangle Pattern - vinanet.vn
H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com
Invivyd CHRO Julie Green sells $31,670 in company stock By Investing.com - Investing.com Canada
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
In vivodyne (NASDAQ: IVVD) holder plans 40,800-share sale - Stock Titan
Invivyd (NASDAQ: IVVD) insider plans 40,800-share sale - Stock Titan
Invivyd (NASDAQ: IVVD) holder to sell 40,800 shares after RSU vest - Stock Titan
Invivyd (NASDAQ: IVVD) holder plans sale of RSU-based shares - Stock Titan
Invivyd (NASDAQ: IVVD) holder to sell 37,741 shares via Morgan Stanley - Stock Titan
Invivyd’s Nasdaq Listing at Risk: Potential Delisting Threatens Financing Access and Market Value - The Globe and Mail
Invivyd Deadline Alert - TMX Newsfile
Invivyd (IVVD) sees 6.3% ownership reported by Perceptive Advisors group - Stock Titan
Invivyd (IVVD): BVF-led group discloses 29.6M shares, 9.99% beneficial stake - Stock Titan
Invivyd earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Invivyd (NASDAQ:IVVD) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo! Finance Canada
Invivyd, Inc. Q2 2026: Revenue $14.29M, EPS $(0.14) — 10-Q Summary - TradingView
Invivyd (IVVD) widens loss, warns on going concern as cash falls to $160M - Stock Titan
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
178,937 |
| Green Julie | Chief Human Resources Officer |
Aug 17 '26 |
Sale |
0.72 |
22,355 |
16,140 |
187,362 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
168,937 |
| Duke William E. | Chief Financial Officer |
Aug 17 '26 |
Sale |
0.72 |
22,355 |
16,140 |
187,362 |
| Duke William E. | Chief Financial Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
168,937 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 17 '26 |
Sale |
0.72 |
37,256 |
26,899 |
314,480 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '26 |
Sale |
0.84 |
30,706 |
25,882 |
283,774 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 17 '26 |
Sale |
0.72 |
20,679 |
14,930 |
195,808 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '26 |
Sale |
0.84 |
17,043 |
14,366 |
178,765 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):